<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2248836&amp;fmt=gif">
MIM Software Inc.

SIR 2021 Annual Scientific Meeting

The End of Not Knowing

The End of Not Knowing

Evolving Dosimetry Software for Your Practice

There are many known limitations to current dosimetry approaches that prevent you from understanding treatment efficacy. Time is short, and more information is needed to make better care decisions. Take your practice from assumptions and spreadsheets to 3D dose and confidence in results.

What Dose did your Patients Receive?

What Dose Did Your Patients Receive?

What is Preventing You from Knowing?

Inadequate Information and Model Limitations

Current options, such as BSA, MIRD, and partition models do not correlate to actual dose delivery.

  • Using BSA, 86% of patients did not receive the target tumor dose of > 120 Gy in a recent Journal of Nuclear Medicine study.1
  • The partition model overestimates the normal liver doses by 2x, according to an International Journal of Radiation Oncology study.2
  • In that same study, it was determined that MIRD Single Compartment was unable to predict tumor dose for any subset of tumor types and sizes compared to voxel-based dosimetry.2

Subsequent Treatments are Limited

Lack of confidence and knowledge of Y90 treatments limits the subsequent treatment options for oncologists.

Question“Should we do a follow-up Y90 if inadequate dose delivery?”

Question“Can we safely consider external beam radiation or another type of procedure after Y90?”

MIM SurePlan™ LiverY90

A Comprehensive Solution for Y90

MIM SurePlan LiverY90 provides timesaving tools for liver and tumor segmentation, deformable registration, and post-treatment dosimetry using Y90-PET and Bremsstrahlung SPECT.

Know Your Dose the Day of Treatment

Patient-specific dosimetry overcomes the uncertainty that the existing planning methods do not correlate with the actual dose delivered.

Empower Your Oncologists

With patient-specific dosimetry, referrers have increased confidence that Y90 is a more legitimate treatment option. Make the most effective treatment path available to your patient by opening up subsequent treatment options using the knowledge gained.

Timesaving Tools

MIM SurePlan LiverY90 is specifically engineered for Y90, making efficiency a top priority. A study3 in the Journal of Nuclear Medicine demonstrated a 70% reduction in time compared to manual outlining of the liver.

Patient Specific Voxel-based Post-Op Dosimetry

Calculate dose using Y90-PET and Bremsstrahlung SPECT. Calculate isodose curves/DVH on PET/SPECT using Local Disposition Method or MIRD Kernel.

MIM Software Inc.
Sirtex Medical
MIM Software and Sirtex Medical have collaborated on a partnership to deliver innovative solutions.
MIM Software Inc.

MIM Software Inc. provides practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging. MIM offers solutions for PC and Mac® workstations, as well as mobile iOS and cloud-based platforms. MIM is a privately held company that sells its products globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies.

Copyright © 2021 MIM Software Inc. All Rights Reserved.